Dow Medical College

Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer

Retrieved on: 
Monday, March 25, 2024
Multiple myeloma, Dow Medical College, University, Rachel Haurwitz, Hematology, BCMA, Novartis, Patient, SAN, NCI-designated Cancer Center, European Hematology Association, Merck, Cancer, Reindeer, Society, Therapy, Drug development, Transplant, Lymphoma

SAN DIEGO, March 25, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the appointment of Syed Rizvi, M.D., as Chief Medical Officer effective April 1, 2024.

Key Points: 
  • SAN DIEGO, March 25, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the appointment of Syed Rizvi, M.D., as Chief Medical Officer effective April 1, 2024.
  • "Syed brings to Poseida an impressive combination of industry leadership and highly specialized drug development experience in cell therapy, and I am excited to welcome him to our leadership team during this important period of execution across our clinical stage CAR-T portfolio," said Kristin Yarema, Ph.D., President and Chief Executive Officer of Poseida.
  • Dr. Rizvi most recently served as Chief Medical Officer of Caribou Biosciences, where he was responsible for overall strategy and execution of all clinical development programs.
  • Prior to joining Caribou, he served as Chief Medical Officer at Chimeric Therapeutics, where he helped build the company's pipeline by licensing programs from leading universities and progressing existing programs through the clinical development process.

The Inner Circle acknowledges Amir A. Rasheed as a Distinguished Healthcare Professional

Retrieved on: 
Thursday, March 7, 2024
Houston Methodist West Hospital, Inner circle, Iron-deficiency anemia, Multimedia, Houston Methodist Baytown Hospital, Hematology, Blood, North Shore University Hospital, Dow Medical College, SUNY Downstate Medical Center, St Luke's, State university system, Prognosis, Haemophilia, Internal medicine, Leukemia, Patient, Oncology, Medicine, Multiple myeloma, Medical Center, Diagnosis, Anti-transglutaminase antibodies, Lymphoma, Cancer, Hospital

SUGARLAND, Texas, March 7, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Amir A. Rasheed is acknowledged as a Distinguished Healthcare Professional for his contributions to the fields of Oncology and Hematology.

Key Points: 
  • SUGARLAND, Texas, March 7, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Amir A. Rasheed is acknowledged as a Distinguished Healthcare Professional for his contributions to the fields of Oncology and Hematology.
  • Dr. Rasheed pursued his medical education at Dow Medical College where he earned a medical degree.
  • He then relocated to the United States to complete a residency in internal medicine at the State University of New York Health Science Center at Brooklyn.
  • Known for his compassionate care and clinical excellence, Dr. Rasheed has dedicated his life to delivering the highest standard of quality care to his patients.

The Inner Circle Acknowledges, Amir Rasheed as a Top Pinnacle Healthcare Professional for his contributions to the fields of Oncology and Hematology

Retrieved on: 
Tuesday, June 20, 2023
Lymphoma, SUNY Downstate Medical Center, Internal medicine, Dow Medical College, Hematology, Multiple myeloma, American Board of Internal Medicine, ABIM, State university system, Cancer, Haemophilia, St Luke's, Prognosis, Medicine, Multimedia, Inner circle, Oncology, Houston Methodist West Hospital, American Board of Commissioners for Foreign Missions, Iron-deficiency anemia, Patient, Houston Methodist Sugar Land Hospital, Baylor St. Luke's Medical Center, Medical Center, Blood, Anti-transglutaminase antibodies, Diagnosis, Leukemia, Houston Methodist Baytown Hospital, Nursing

SUGARLAND, Texas, June 20, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Amir Rasheed is acknowledged as a Top Pinnacle Healthcare Professional for his contributions to the fields of Oncology and Hematology.

Key Points: 
  • SUGARLAND, Texas, June 20, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Amir Rasheed is acknowledged as a Top Pinnacle Healthcare Professional for his contributions to the fields of Oncology and Hematology.
  • Dr. Rasheed pursued his medical education at Dow Medical College where he earned a medical degree.
  • He then relocated to the United States to complete a residency in internal medicine at the State University of New York Health Science Center at Brooklyn.
  • Known for his compassionate care and clinical excellence, Dr. Rasheed has dedicated his life to delivering the highest standard of quality care to his patients.

DGAP-News: Sofinnova Partners: AAVantgarde Announces the Appointment of Naveed Shams, M.D., Ph.D. as Chief Development and Medical Officer

Retrieved on: 
Thursday, June 30, 2022
Department, Schepens Eye Research Institute, Board of directors, Dow Medical College, Patient, Sofinnova, Biotechnology, OPKO Health, Lead, Gene, Harvard Medical School, Retina, AAV, Industry, AIFA, Partner, Translational research, CDMO, MILAN, Investment, Clinical trial, University, RNA, ITALY, Macular degeneration, Stargardt disease, Board, Leadership, Therapy, Management, Pharmaceutical industry, Vaccine, Fine chemical, Medical device, Usher, Medicine, Microbiology, Ophthalmology, Genentech, Ranibizumab, Genetics

Sofinnova Partners: AAVantgarde Announces the Appointment of Naveed Shams, M.D., Ph.D. as Chief Development and Medical Officer

Key Points: 
  • Sofinnova Partners: AAVantgarde Announces the Appointment of Naveed Shams, M.D., Ph.D. as Chief Development and Medical Officer
    The issuer is solely responsible for the content of this announcement.
  • AAVantgarde Announces the Appointment of Naveed Shams, M.D., Ph.D. as Chief Development and Medical Officer
    MILAN, ITALY / ACCESSWIRE / June 30, 2022 / AAVantgarde Bio , a biotechnology start-up that is developing gene therapies for inherited retinal disorders based on Adeno-Associated Viral (AAV) vectors, announced the appointment of Naveed Shams, M.D., Ph.D., as Chief Development and Medical Officer (CDMO).
  • "Naveed is a seasoned biotech executive and a highly respected clinician with over three decades of expertise in developing and commercializing ophthalmic drugs globally.
  • Dr. Shams received his medical degree from Dow Medical College in Karachi, Pakistan, and his Ph.D. in Microbiology & Immunology from the University of South Carolina.

Nanoscope Therapeutics Appoints Two Pharmaceutical Industry Veterans as Scientific and Clinical Advisors

Retrieved on: 
Wednesday, May 25, 2022
Department, Chemistry, Retinitis pigmentosa, MBA, Company, University, Dow Medical College, Retina, Doctor of Philosophy, Geographic atrophy, Patient, Genetic testing, Spark Therapeutics, Tufts University School of Medicine, GA, Therapy, BA, Retinal degeneration, MCO, Faculty, D Grubu, ProQR, Corneal transplantation, Novartis, University of California, FDA, AMD, Industry, Harvard University, RP, Medical school, Santen Pharmaceutical, Board, Genentech, Wound healing, Harvard Medical School, Eye, MD, CEO, Pharmaceutical industry, Medical device, Atomic de Broglie microscope, Stargardt disease, Indiana University, Ophthalmology

"We are extremely pleased to have these distinguished leaders join our team of advisors.

Key Points: 
  • "We are extremely pleased to have these distinguished leaders join our team of advisors.
  • "Nanoscope has already begun to demonstrate the tremendous potential of this approach, including extraordinary efficacy and good tolerability in severely visually impaired individuals.
  • At Genentech, Dr. Shams helped to establish the Ophthalmic Clinical R&D Group and led the development of Lucentis through approval.
  • Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists.

Los Angeles Cancer Network Opens New Location in Torrance

Retrieved on: 
Tuesday, March 29, 2022
New York Medical College, Internal medicine, Degenerative disease, Leadership, Cancer, Dow Medical College, Hindi, Suite, Oncology, Madison Street, CA, Patient, Partnership, Medicine, Medical device

TORRANCE, Calif., March 29, 2022 /PRNewswire/ -- Los Angeles Cancer Network (LACN) has been providing care for cancer and blood disorders in the Los Angeles community for over three decades and continues to grow.

Key Points: 
  • TORRANCE, Calif., March 29, 2022 /PRNewswire/ -- Los Angeles Cancer Network (LACN) has been providing care for cancer and blood disorders in the Los Angeles community for over three decades and continues to grow.
  • Their newest location will open on March 28, 2022 at 23441 Madison Street, Suite 215, Torrance, California 90505.
  • Los Angeles Cancer Network Opens Tenth Blood & Cancer Center in Torrance, CA
    Managing partner, Dr. Boris Bagdasarian, stated "keeping patientcare close to home is a top priority for our organization.
  • About Los Angeles Cancer Network:
    The mission of The Los Angeles Cancer Network is to provide unparalleled care to each patient that comes through our doors.

Caribou Biosciences Appoints Syed Rizvi, M.D., as Chief Medical Officer

Retrieved on: 
Tuesday, January 18, 2022
Patient, Research, BCMA, Lymphoma, American Society of Hematology, Disclosure, Legend, NK, Dow Medical College, Private Securities Litigation Reform Act, RNA, Genome, Rachel Haurwitz, Multiple myeloma, Safety, Novartis, Transplant, Merck, GLOBE, Society, IND, Leadership, Health, DNA, Lymphatic system, Bristol Myers Squibb, U.S. Securities and Exchange Commission, Celgene, Nasdaq, American Society of Clinical Oncology, Reindeer, Phenotype, CRISPR, Efficiency, Head, Drug development, Therapy, Hematology, Cancer, CRISPR/Cpf1, Prospectus, Security (finance), Risk, Pharmaceutical industry

BERKELEY, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Syed Rizvi, M.D., to the newly created position of chief medical officer.

Key Points: 
  • BERKELEY, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Syed Rizvi, M.D., to the newly created position of chief medical officer.
  • We have a transformative year ahead of us and I am delighted to welcome Syed to the Caribou team.
  • Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases.
  • Caribou Biosciences and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.
    ABECMA and BREYANZI are registered trademarks of Bristol Myers Squibb.